Redx Pharma PLC (AIM:REDX) chief medical officer Dr Jane Robertson speaks to Proactive's Thomas Warner after announcing that phase II data from the first group of patients being administered RXC004 for biliary tract cancer was not enough to support further development.
Robertson highlights RXC004's potential for use as a combination therapy.